About SfPM
Functional precision medicine is at an inflection point in cancer care. Genomics has transformed oncology, yet molecular data alone still falls short in predicting patient responses. The next decade requires marrying tumor profiling with systematic, scalable functional testing directly on patient-derived tissue and models to guide therapy, accelerate discovery, and benefit patients.
The time is now: organoids, tissue models, single-cell profiling, artificial intelligence, and related technologies are now mature enough to inform both clinical decision-making and drug development, while the policy environment is increasingly receptive to evidence-driven implementation. SfPM is seizing this moment to unite researchers, clinicians, biopharma, funders, and patient advocates around a shared national vision: making functional precision medicine a rigorous, clinically actionable, and measurable part of how we use precision medicine to treat cancer.
Over the next several years, SfPM is focused on four priorities:
A national strategic plan: defining the roadmap academia, biopharma, government, and patient groups must take together to move the field forward.
An expanded community: broadening the expertise and representation, driving functional precision medicine through inclusive events and new collaborations.
A funders coalition: building relationships with governmental and non-governmental funders to catalyze early high-impact projects.
Flagship projects: coordinated, high-impact initiatives that demonstrate what the field can achieve together.
Board of Directors
Karin Langenberg, MD, PhD
Vice President
Princess Máxima Center for Pediatric Oncology
Keith Ligon, MD, PhD
Secretary
Dana-Farber Cancer Institute, Harvard Medical School
Jeff Tyner, PhD
Treasurer
Oregon Health Sciences University
Noah Berlow, PhD
Board Member
First Ascent Biomedical
Bruce Yeager
Board Member - Commercial Sector
G2E Enterprises, Inc.
Jesse Boehm, PhD
Co-President
Massachusetts Institute of Technology
Alice Soragni, PhD
Co-President
University of Colorado Anschutz
Christian Regenbrecht, PhD
Board Member - Commercial Sector
GSK
Joan Montero, PhD
Board Member
University of Barcelona
Former Directors
Diana Azzam, PhD
Florida International University
Sara Cherry, PhD
University of Pennsylvania
Chris Kemp, PhD
Fred Hutchinson Cancer Research Center
Anthony Letai, MD, PhD
Director, National Cancer Institute